NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic
NeoGenomics announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca's recently approved targeted therapy Truqap. PTEN IHC CDx extends the company's reach into urologic oncology. Performed by NeoGenomics' pathologists across its national oncology laboratory network, the test is available as a standalone order or as part of NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup that combines CGP and cancer-type-directed IHC testing in a single order built to evolve with new treatment options.
NeoGenomics announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma.
The test identifies PTEN protein loss, also known as PTEN deficiency, in patients who may be eligible for AstraZeneca's recently approved targeted therapy Truqap.
PTEN IHC CDx extends the company's reach into urologic oncology.
Performed by NeoGenomics' pathologists across its national oncology laboratory network, the test is available as a standalone order or as part of NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup that combines CGP and cancer-type-directed IHC testing in a single order built to evolve with new treatment options.